Ashley Adams
CEO and Biotechnology Analyst ,
Lickety-Split Analytics
Follow
About Ashley
Ashley Adams is the CEO and biotechnology analyst of Lickety-Split Analytics, an independent equity research firm founded in 2020. She specializes in identifying undervalued small-cap biotech companies focused on high-growth potential therapeutic areas, particularly metabolic disorders such as NASH/MASH and obesity. Her prior experience includes serving as the senior equity analyst at PVG Asset Management.
Ashley's Articles
Grail Inc. (GRAL) is the developer of Multi-Cancer Early Detection test kits, and it recently published results focused on a subset of prostate cancer in their studies. The market reacted quite negatively to the release, but that presents a potential entry opportunity, writes Ashley Adams, CEO and biotechnology analyst at Lickety-Split Analytics.
Ashley Adams
BIOTECHNOLOGY
Tickers: GRAL